Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating

EF Hutton Acquisition Co. I upgraded shares of Invivyd (NASDAQ:IVVD - Free Report) to a strong-buy rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Invivyd in a research note on Tuesday.

Invivyd Stock Performance

Shares of IVVD traded up $0.01 on Wednesday, hitting $0.90. 357,554 shares of the stock traded hands, compared to its average volume of 633,168. Invivyd has a one year low of $0.81 and a one year high of $5.20. The company has a market capitalization of $107.51 million, a PE ratio of -0.50 and a beta of 0.63. The business has a 50 day simple moving average of $0.99 and a 200 day simple moving average of $1.40.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.03). The business had revenue of $2.26 million during the quarter, compared to analyst estimates of $4.91 million. On average, equities analysts expect that Invivyd will post -0.6 earnings per share for the current year.

Institutional Trading of Invivyd

Several large investors have recently added to or reduced their stakes in the business. Chase Investment Counsel Corp purchased a new position in Invivyd during the first quarter valued at approximately $271,000. SG Americas Securities LLC bought a new position in Invivyd in the 1st quarter worth $56,000. Vanguard Group Inc. increased its stake in Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock worth $11,594,000 after buying an additional 97,496 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Invivyd during the first quarter valued at about $905,000. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Invivyd by 21.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company's stock valued at $1,933,000 after acquiring an additional 77,603 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.